ストックスクリーナーアプリを入手
298.16
1.68%
4.92
プレマーケット:
295.06
-3.10
-1.04%
前日終値:
$293.24
開ける：
$295.25
24時間の取引高:
324.42K
Relative Volume:
0.61
時価総額：
$13.45B
収益：
$2.99B
当期純損益:
$1.21B
株価収益率:
11.90
EPS:
25.06
ネットキャッシュフロー:
$1.13B
1週間 パフォーマンス:
-0.80%
1か月 パフォーマンス:
+3.33%
6か月 パフォーマンス:
-18.62%
1年 パフォーマンス:
-9.15%
1日の値動き範囲:
$295.01
$299.83
1週間の範囲:
$291.72
$301.75
52週間の値動き範囲:
$266.98
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
UTHR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
298.16 | 13.56B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
151.54 | 70.46B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 47.78B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.69 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.01 | 19.16B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
Pulmonary Arterial Hypertension Drug Market Forecast to 2032: - openPR.com
United Therapeutics Announces Q2 Earnings Date: Key Details for Biotech Investment Community - Stock Titan
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment - Yahoo Finance
United Therapeutics Puts Big Bets On Tyvaso’s Trial Results - Finimize
United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says - MarketScreener
United Therapeutics (UTHR) Awaits Key Catalyst with Positive Ris - GuruFocus
United Therapeutic's: The Brands First Hydrogen Helicopter - Energy Digital Magazine
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term - Yahoo Finance
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for Investors - TipRanks
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - Insider Monkey
United Therapeutics (UTHR) Price Target Adjustment by Morgan Sta - GuruFocus
United Therapeutics (UTHR) Price Target Trimmed by Morgan Stanle - GuruFocus
United Therapeutics (UTHR): JP Morgan Adjusts Price Target | UTH - GuruFocus
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize
United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lowered by UBS | UTHR Stock News - GuruFocus
United Therapeutics’ Promising Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
United Therapeutics (UTHR) Maintains Buy Rating, Price Target Lo - GuruFocus
United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study - Insider Monkey
United Therapeutics EVP Mahon sells $3.14 million in UTHR stock - Investing.com
United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment - TipRanks
United Therapeutics’ Ralinepag Study: A Potential Game-Changer in PAH Treatment - TipRanks
United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock? - Yahoo Finance
United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus
United Therapeutics: Tanking On Rival's PAH DataI'd Consider Buying Stock (NASDAQ:UTHR) - Seeking Alpha
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com
United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News
Liquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH asset - Seeking Alpha
Treprostinil Saga Continues - JD Supra
United Therapeutics president sells shares worth $3.7 million - MSN
Leerink Partners maintains positive outlook on United Therapeutics stock By Investing.com - Investing.com South Africa
Leerink Partners maintains positive outlook on United Therapeutics stock - Investing.com
United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald - Defense World
United Therapeutics (UTHR) Receives New Overweight Rating from C - GuruFocus
Forecasting The Future: 7 Analyst Projections For United Therapeutics - Benzinga
United Therapeutics (UTHR) Receives Overweight Rating from Canto - GuruFocus
United Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - Yahoo Finance
Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report? - Yahoo Finance
Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360
United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 10 '25 |
Sale |
300.31 |
11,000 |
3,303,394 |
36,781 |
1.71%
0.19%
大文字化:
|
ボリューム (24 時間):